Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4T9RS)

Drug Name
ATN-161 Drug Info
Synonyms PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan
Cross-matching ID
PubChem CID
9960285
CAS Number
CAS 262438-43-7
TTD Drug ID
D00QVT

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.10 7.07e-3 101/150 (67.33%) HSPA6;HNRNPA3;HSPA2;...
Pyrimidine metabolism 1.96 3.53e-3 40/56 (71.43%) TYMS;CTPS1;UCK2;...
DNA replication 1.94 2.36e-3 34/36 (94.44%) PCNA;MCM5;MCM2;...
Mismatch repair 1.75 3.18e-2 22/23 (95.65%) PCNA;MSH6;EXO1;...
Kaposi sarcoma-associated herpesvirus infection -1.64 4.57e-2 172/193 (89.12%) NFKB1;ATG14;MAPK10;...
PPAR signaling pathway -1.66 4.44e-2 66/74 (89.19%) ACAA1;PPARG;ME1;...
Parathyroid hormone synthesis, secretion and action -1.66 4.36e-2 98/106 (92.45%) TNFSF11;PDE4B;ADCY2;...
Antigen processing and presentation -1.67 4.50e-2 60/78 (76.92%) HLA-G;HSP90AB1;CIITA;...
Shigellosis -1.68 3.95e-2 180/246 (73.17%) GLMN;NFKB1;ATG14;...
Salmonella infection -1.68 4.07e-2 198/249 (79.52%) DCTN4;HSP90AA1;EXOC5;...
Primary immunodeficiency -1.70 3.06e-2 33/38 (86.84%) AICDA;CD79A;TAP1;...
Adherens junction -1.72 2.49e-2 63/71 (88.73%) WAS;TGFBR1;ACP1;...
Chemical carcinogenesis -1.73 2.48e-2 186/281 (66.19%) CYP2A6;KPNA5;CYP2C9;...
Thyroid cancer -1.74 1.95e-2 36/37 (97.3%) PPARG;TPM3;GADD45A;...
Rheumatoid arthritis -1.74 2.07e-2 78/93 (83.87%) CD28;VEGFA;FLT1;...
IL-17 signaling pathway -1.77 1.87e-2 84/94 (89.36%) TRAF3IP2;HSP90AA1;NFKB1;...
Th1 and Th2 cell differentiation -1.77 2.01e-2 80/92 (86.96%) MAPK1;PRKCQ;RBPJ;...
Apoptosis -1.78 2.06e-2 126/168 (75%) NTRK1;CTSO;MAP3K5;...
NF-kappa B signaling pathway -1.80 1.91e-2 90/104 (86.54%) SYK;LTB;TRADD;...
Mitophagy -1.82 1.74e-2 56/68 (82.35%) OPTN;BCL2L13;TFE3;...
Type I diabetes mellitus -1.86 6.38e-3 38/43 (88.37%) PTPRN2;HLA-A;HLA-DQA1;...
Inflammatory bowel disease -1.87 7.09e-3 58/65 (89.23%) IL12B;NOD2;IL21;...
Metabolism of xenobiotics by cytochrome P450 -1.91 6.38e-3 49/77 (63.64%) CYP2A6;CYP2C9;UGT2A3;...
Autoimmune thyroid disease -1.94 1.82e-3 46/53 (86.79%) IFNA2;CD28;HLA-G;...
Lysosome -1.96 0.00e+0 115/128 (89.84%) GGA1;SLC17A5;ENTPD4;...
Allograft rejection -2.01 0.00e+0 32/38 (84.21%) HLA-DQB1;FAS;FASLG;...
Retinol metabolism -2.11 0.00e+0 41/68 (60.29%) HSD17B6;CYP26A1;UGT2B4;...
Viral myocarditis -2.14 0.00e+0 53/60 (88.33%) CYCS;HLA-A;RAC1;...
Hematopoietic cell lineage -2.16 0.00e+0 90/99 (90.91%) IL5;ITGA5;ITGA4;...
Graft-versus-host disease -2.19 0.00e+0 32/42 (76.19%) HLA-A;HLA-DQA1;CD86;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H